FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783818> ?p ?o ?g. }

• W4220783818 abstract "Background Individuals with inflammatory bowel disease (IBD) who are immunocompromised may have a reduced serological response to the SARS-CoV-2 vaccine. We investigated serological responses following 1 st , 2 nd , and 3 rd doses of SARS-CoV-2 vaccination in those with IBD. Methods A prospective cohort study of persons with IBD ( n = 496) assessed serological response 1–8 weeks after 1 st dose vaccination, 1–8 weeks after 2 nd dose, 8 or more weeks after 2 nd dose, and at least 1 week after 3 rd dose. Seroconversion and geometric mean titer (GMT) with 95% confidence intervals (CI) were assessed for antibodies to the SARS-CoV-2 spike protein. Multivariable linear regression models assessed the adjusted fold change (FC) in antibody levels. Results Seroconversion and GMT increased from post-1 st dose to 1–8 weeks post-2 nd dose (81.6%, 1814 AU/mL vs. 98.7%, 9229 AU/mL, p <0.001), decreased after 8 weeks post-2 nd dose (94.9%, 3002 AU/mL, p <0.001), and rebounded post-3 rd dose (99.6%, 14639 AU/mL, p <0.001). Prednisone was the only IBD-related medication associated with diminished antibody response after 3 rd -dose vaccination (FC: 0.07 [95% CI: 0.02, 0.20]). Antibody levels steadily decline following the 2 nd (FC: 0.92 [95% CI: 0.90, 0.94] per week) and 3 rd dose (FC: 0.88 [95% CI: 0.84, 0.92] per week) of the SARS-CoV-2 vaccine. Conclusion A three-dose regimen of vaccination to SARS-CoV-2 yields a robust antibody response for those with IBD across all classes of IBD therapies except for prednisone. The decaying antibody levels following the 3 rd dose of the vaccine should be monitored in future studies." @default.
• W4220783818 created "2022-04-03" @default.
• W4220783818 creator A5003845494 @default.
• W4220783818 creator A5006500798 @default.
• W4220783818 creator A5008149243 @default.
• W4220783818 creator A5012159869 @default.
• W4220783818 creator A5017585326 @default.
• W4220783818 creator A5018400920 @default.
• W4220783818 creator A5027876343 @default.
• W4220783818 creator A5030821767 @default.
• W4220783818 creator A5033409629 @default.
• W4220783818 creator A5035437112 @default.
• W4220783818 creator A5045216057 @default.
• W4220783818 creator A5052911433 @default.
• W4220783818 creator A5054942512 @default.
• W4220783818 creator A5056711512 @default.
• W4220783818 creator A5059959437 @default.
• W4220783818 creator A5074103913 @default.
• W4220783818 creator A5083384050 @default.
• W4220783818 creator A5086859015 @default.
• W4220783818 creator A5090179117 @default.
• W4220783818 date "2022-03-18" @default.
• W4220783818 modified "2023-10-02" @default.
• W4220783818 title "Serological Responses to the First Three Doses of SARS-CoV-2 Vaccination in Inflammatory Bowel Disease: A Prospective Cohort Study" @default.
• W4220783818 cites W3087924281 @default.
• W4220783818 cites W3094105410 @default.
• W4220783818 cites W3111255098 @default.
• W4220783818 cites W3111590711 @default.
• W4220783818 cites W3119736579 @default.
• W4220783818 cites W3145977403 @default.
• W4220783818 cites W3154888372 @default.
• W4220783818 cites W3158750369 @default.
• W4220783818 cites W3197081215 @default.
• W4220783818 cites W3198016518 @default.
• W4220783818 cites W3198593273 @default.
• W4220783818 cites W3202238098 @default.
• W4220783818 cites W3207851273 @default.
• W4220783818 cites W3211135479 @default.
• W4220783818 cites W3211284609 @default.
• W4220783818 cites W3212286463 @default.
• W4220783818 cites W3212692368 @default.
• W4220783818 cites W3212824308 @default.
• W4220783818 cites W4205483821 @default.
• W4220783818 cites W4206932932 @default.
• W4220783818 cites W4210350488 @default.
• W4220783818 cites W4211035513 @default.
• W4220783818 cites W4212768856 @default.
• W4220783818 cites W4213322023 @default.
• W4220783818 cites W4214700028 @default.
• W4220783818 cites W4225636140 @default.
• W4220783818 cites W4281735446 @default.
• W4220783818 doi "https://doi.org/10.1101/2022.03.16.22272440" @default.
• W4220783818 hasPublicationYear "2022" @default.
• W4220783818 type Work @default.
• W4220783818 citedByCount "1" @default.
• W4220783818 countsByYear W42207838182022 @default.
• W4220783818 crossrefType "posted-content" @default.
• W4220783818 hasAuthorship W4220783818A5003845494 @default.
• W4220783818 hasAuthorship W4220783818A5006500798 @default.
• W4220783818 hasAuthorship W4220783818A5008149243 @default.
• W4220783818 hasAuthorship W4220783818A5012159869 @default.
• W4220783818 hasAuthorship W4220783818A5017585326 @default.
• W4220783818 hasAuthorship W4220783818A5018400920 @default.
• W4220783818 hasAuthorship W4220783818A5027876343 @default.
• W4220783818 hasAuthorship W4220783818A5030821767 @default.
• W4220783818 hasAuthorship W4220783818A5033409629 @default.
• W4220783818 hasAuthorship W4220783818A5035437112 @default.
• W4220783818 hasAuthorship W4220783818A5045216057 @default.
• W4220783818 hasAuthorship W4220783818A5052911433 @default.
• W4220783818 hasAuthorship W4220783818A5054942512 @default.
• W4220783818 hasAuthorship W4220783818A5056711512 @default.
• W4220783818 hasAuthorship W4220783818A5059959437 @default.
• W4220783818 hasAuthorship W4220783818A5074103913 @default.
• W4220783818 hasAuthorship W4220783818A5083384050 @default.
• W4220783818 hasAuthorship W4220783818A5086859015 @default.
• W4220783818 hasAuthorship W4220783818A5090179117 @default.
• W4220783818 hasBestOaLocation W42207838181 @default.
• W4220783818 hasConcept C126322002 @default.
• W4220783818 hasConcept C159654299 @default.
• W4220783818 hasConcept C188816634 @default.
• W4220783818 hasConcept C203014093 @default.
• W4220783818 hasConcept C22070199 @default.
• W4220783818 hasConcept C22889606 @default.
• W4220783818 hasConcept C2777451964 @default.
• W4220783818 hasConcept C2778260677 @default.
• W4220783818 hasConcept C2779134260 @default.
• W4220783818 hasConcept C32611913 @default.
• W4220783818 hasConcept C44249647 @default.
• W4220783818 hasConcept C45189115 @default.
• W4220783818 hasConcept C71924100 @default.
• W4220783818 hasConcept C72563966 @default.
• W4220783818 hasConcept C90924648 @default.
• W4220783818 hasConceptScore W4220783818C126322002 @default.
• W4220783818 hasConceptScore W4220783818C159654299 @default.
• W4220783818 hasConceptScore W4220783818C188816634 @default.
• W4220783818 hasConceptScore W4220783818C203014093 @default.
• W4220783818 hasConceptScore W4220783818C22070199 @default.
• W4220783818 hasConceptScore W4220783818C22889606 @default.
• W4220783818 hasConceptScore W4220783818C2777451964 @default.
• W4220783818 hasConceptScore W4220783818C2778260677 @default.

• next